From Idea to Market: Ep 11 - Built to Last or Built to Sell?

Send us Fan MailIs your med tech company built to last, or built to sell? Voices from inside Stryker, XRSynergies, FIOS Health, and physician contract law explain why exit strategy is a design choice founders make on day one — whether they realize it or not.In 2024, med tech M&A reached a record $474 billion in global transaction value. For most successful device startups, the path to broad patient reach runs through acquisition — and that reality shapes how experienced founders structure their companies from the moment of incorporation. Corporate form, consulting agreements, equity design, and quality systems all encode an implied destination long before an acquirer ever calls.Robert Cohen (VP of Innovation & Technology, Stryker Orthopedics) describes how acquisition conversations actually unfold — why the clinical case comes before any discussion of cost of goods or time to market, and how incorporating as a C corporation from day one made his second company's acquisition by Mako Surgical dramatically easier. Marie-Isabelle Batthyány (founder & CEO, XRSynergies) explains building a company that is "easy to take over," from phantom share programs to diligence-ready quality management. Attorney Emily Ast unpacks the shift from long royalty streams toward milestone-based deal structures, and Charles Lawrie (co-founder, FIOS Health) makes the case for clinical validation as the founder's contribution, with commercial scaling left to the acquirer.Whether you're a surgeon with a device idea, a founder weighing an LLC against a C corporation, or a clinician curious how acquisitions preserve or lose the clinical knowledge behind a product, this episode maps the decisions that determine what your company becomes.⏱️ Chapters:00:00 Introduction: exit as a design choice, not a finish line03:00 Meet the founders, acquirers, and attorneys05:06 Early structural choices that define what a company becomes06:04 What a med tech acquirer is actually buying08:12 How acquisition conversations start: the clinical case first10:24 Structuring a startup to be acquisition-ready12:57 Path dependency: early decisions that get expensive to reverse14:17 Why a C corporation from day one speeds diligence16:31 Royalties vs milestone payments in med tech deals19:34 Why acquisitions underperform: knowledge transfer and retention24:18 Building to sell: clinical validation vs commercial scaleListen to the AHF Podcast on your preferred platform:Buzzsprout: https://ahfpodcast.buzzsprout.comApple Podcasts: https://podcasts.apple.com/us/podcast/ahf-podcast/id1749521487Spotify: https://open.spotify.com/show/5CrGJyvRiQFTCU3FFFVvHcLinkedIn: https://www.linkedin.com/showcase/ahf-podcastYouTube: https://www.youtube.com/@anteriorhipfoundationHomepage: https://anteriorhipfoundation.comThis podcast is intended for educational and informational purposes only.The content discussed does not constitute medical advice and should not be used as a substitute for professional judgment. Clinicians should rely on their own training, experience, and clinical decision-making when applying information from this discussion.#AnteriorHipFoundation #AHFPodcast #MedTech #MedicalDevices #MedTechAcquisitions #ExitStrategy #MedicalDeviceStartup #OrthopedicSurgery #HealthcareInnovation #DeviceDevelopment #FromIdeaToMarket #Stryker